Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT04815720 is registered in ClinicalTrials.gov with Vaccinex Inc. as lead sponsor.

NCT NCT04815720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04815720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Vaccinex Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 9, 2021
Completion date
July 24, 2024
Enrollment
49 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent/metastatic squamous cell carcinoma of the head and neck (hnscc)